Thought Leadership
Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 23 posts
October 20, 2020 | Blog
Digital Therapeutics as Digital Companions: Models for Effective Pharma Partnerships
Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.
September 22, 2020 | Blog
CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA
CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.
August 5, 2020 | Blog
Misconceptions of the 340B Drug Discount Program
Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.
August 5, 2020 | Infographics
10 Myths About the 340B Drug Pricing Program That You Should Know About
July 14, 2020 | Blog
Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World
CBPartners’ in collaboration with Eric Bernath, explores the current USA access landscape, processes and pitfalls for companion digital therapeutics (DTx), as well as how the space is likely to evolve in the future, and lays out some best practices as suggested by USA payers to maximize chances of reimbursement.